Drug Profile


Alternative Names: AP 2/09-DS; AP-12009; AP-2/09; OT-101; OT-201; Personalised dosing TGF-beta antisense; TGF-beta antisense

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Antisense Pharma
  • Developer Autotelic; Oncotelic
  • Class Antineoplastics; Oligodeoxyribonucleotides; Thionucleotides
  • Mechanism of Action Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II/III Malignant melanoma; Pancreatic cancer
  • No development reported Colorectal cancer
  • Discontinued Anaplastic astrocytoma

Most Recent Events

  • 07 Sep 2016 Discontinued - Phase-II for Anaplastic astrocytoma (Late-stage disease, Recurrent, Second-line therapy or greater) in Israel, Georgia (Intratumoural) (Oncotelic pipeline, September 2016)
  • 07 Sep 2016 Discontinued - Phase-III for Anaplastic astrocytoma (Late-stage disease, Recurrent, Second-line therapy or greater) in United Kingdom, Taiwan, Spain, Poland, South Korea, Hungary, France, Brazil, Argentina, USA, India, Russia, Germany, Mexico, Canada, Austria (Intratumoural) (Oncotelic pipeline, September 2016)
  • 07 Sep 2016 Trabedersen is still in phase II/III trials for Pancreatic cancer in Germany (Oncotelic pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top